AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29515144 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation
Number of subjects: 2096
Study 29515144 — intervention group
Group type: EXPERIMENTAL
Intervention: Recall
Number of subjects: 2096
Study 26368833 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal Cawthorne & Cooksey protocol (n = 42)
Number of subjects: 82
Study 26368833 — intervention group
Group type: COMPARATOR
Intervention: Conventional Cawthorne & Cooksey protocol (n = 40)
Number of subjects: 82
Study 24962502 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual minority girls (SMGs)
Number of subjects: 564
Study 24962502 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterosexual girls with ARA exposure
Number of subjects: 564
Study 24962502 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual minority girls (SMGs) without ARA exposure
Number of subjects: 564
Study 22223180 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept (320 mg loading dose followed by 160 mg weekly)
Number of subjects: 83
Study 22223180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 20638409 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured exercise schedules
Number of subjects: 140
Study 20638409 — intervention group
Group type: COMPARATOR
Intervention: Non-structured exercise recommendations (Control)
Number of subjects: 140
Study 17189087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal-thickened formula
Number of subjects: 63
Study 17189087 — intervention group
Group type: COMPARATOR
Intervention: Postural therapy
Number of subjects: 63
Study 15279345 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine infiltration
Number of subjects: 142
Study 15279345 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bupivacaine)
Number of subjects: 142
Study 12170040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib, 20 mg
Number of subjects: 60
Study 12170040 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib, 40 mg
Number of subjects: 60
Study 12170040 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 60
Study 12170040 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 10094236 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 40
Study 10094236 — intervention group
Group type: COMPARATOR
Intervention: Phenelzine
Number of subjects: 40
Study 10094236 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (at follow-up)
Number of subjects: 40
Study 8586311 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound (TVS)
Number of subjects: 91
Study 8586311 — intervention group
Group type: COMPARATOR
Intervention: Transabdominal ultrasound (TAS)
Number of subjects: 91
Study 2378770 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2.5 mg kg‐1 with adrenaline 5 micrograms ml‐1
Number of subjects: 12
Study 2378770 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 2.5 mg kg‐1 without adrenaline
Number of subjects: 12
Study 796476 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame (2.7 g/day)
Number of subjects: 100
Study 796476 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 100
Study 796476 — intervention group
Group type: COMPARATOR
Intervention: Aspartame and placebo
Number of subjects: 100
Study 30261781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 40
Study 30261781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28242580 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored education program for falls prevention using home floor plans (n=25)
Number of subjects: 60
Study 28242580 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care (exercises) + Tailored education program (n=25)
Number of subjects: 60
Study 28242580 — intervention group
Group type: COMPARATOR
Intervention: Standard care (exercises) (n=26)
Number of subjects: 60
Study 25796408 — intervention group
Group type: EXPERIMENTAL
Intervention: 50:50 anorganic bovine bone and autologous bone
Number of subjects: 20
Study 25796408 — intervention group
Group type: COMPARATOR
Intervention: anorganic bovine bone alone
Number of subjects: 20
Study 23073395 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based dyspnea self-management program (eDSMP)
Number of subjects: 125
Study 23073395 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face dyspnea self-management program (fDSMP)
Number of subjects: 125
Study 23073395 — intervention group
Group type: COMPARATOR
Intervention: General health education (GHE)
Number of subjects: 125
Study 23073395 — intervention group
Group type: EXPERIMENTAL
Intervention: DSMPs (eDSMP and fDSMP combined)
Number of subjects: 125
Study 21718738 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa vaccine (Boostrix(®))
Number of subjects: 293
Study 18637602 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intrathecal and epidural magnesium (50 mg of 5% Mg and 2% Mg at a rate of 100 mg/hr)
Number of subjects: 80
Study 18637602 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal 10 mg of Bupivacaine 0.5% plus 25 microg of Fentanyl plus 50 mg of 5% Mg
Number of subjects: 80
Study 18637602 — intervention group
Group type: COMPARATOR
Intervention: Intrathecal 10 mg of Bupivacaine 0.5% plus 25 microg of Fentanyl plus 0.9% NaCl solution
Number of subjects: 80
Study 17160911 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0
Study 17160911 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 0
Study 17160911 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate-statin combination therapy
Number of subjects: 0
Study 15344449 — intervention group
Group type: EXPERIMENTAL
Intervention: Voxel-based cortical thickness estimation method
Number of subjects: 50
Study 15344449 — intervention group
Group type: COMPARATOR
Intervention: Control group of 23 healthy subjects
Number of subjects: 50
Study 12585144 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and GBYL (Group B)
Number of subjects: 81
Study 12585144 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and GBYL plus moxibustion (Group C)
Number of subjects: 81
Study 12585144 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy and placebo (Group A)
Number of subjects: 81
Study 9730668 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment, 0.2 IU/kg/body weight daily for 3 years
Number of subjects: 69
Study 9730668 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2) with 1-year observation followed by 3 years of GH treatment, 0.2 IU/kg/body weight daily
Number of subjects: 69
Study 9730668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (GH treatment)
Number of subjects: 69
Study 7992939 — intervention group
Group type: EXPERIMENTAL
Intervention: Orth‐Evac group (OGr)
Number of subjects: 30
Study 7992939 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcotrans Plus group (SGr)
Number of subjects: 30
Study 7992939 — intervention group
Group type: COMPARATOR
Intervention: Control group (CGr)
Number of subjects: 30
Study 7992939 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 2736968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 25
Study 2736968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 25
Study 2736968 — intervention group
Group type: COMPARATOR
Intervention: Dopamine and Dobutamine
Number of subjects: 25
Study 127655 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus RAJI immunotherapy
Number of subjects: 16
Study 127655 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 16
Study 31755166 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat and moisture exchanger (HME) worn during intense cold air exercise
Number of subjects: 13
Study 31755166 — intervention group
Group type: COMPARATOR
Intervention: No heat and moisture exchanger (without HME) during intense cold air exercise
Number of subjects: 13
Study 31109760 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intensity progression during cardiac rehabilitation
Number of subjects: 238
Study 27912161 — intervention group
Group type: EXPERIMENTAL
Intervention: TaperGuard EVAC tube with subglottic suctioning every 6 hours
Number of subjects: 276
Study 27912161 — intervention group
Group type: COMPARATOR
Intervention: Conventional tube
Number of subjects: 276
Study 27912161 — intervention group
Group type: EXPERIMENTAL
Intervention: TaperGuard EVAC tube
Number of subjects: 276
Study 26086641 — intervention group
Group type: EXPERIMENTAL
Intervention: VLBW children
Number of subjects: 120
Study 26086641 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA children
Number of subjects: 120
Study 26086641 — intervention group
Group type: COMPARATOR
Intervention: Term AGA children
Number of subjects: 120
Study 23941313 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (active treatment)
Number of subjects: 792
Study 23941313 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 792
Study 23941313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral smoking cessation treatment (CBT)
Number of subjects: 792
Study 23941313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment for depression
Number of subjects: 792
Study 23941313 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized behavioral support
Number of subjects: 792
Study 21623607 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 57
Study 21623607 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 57
Study 21623607 — intervention group
Group type: EXPERIMENTAL
Intervention: Both open and laparoscopic surgery
Number of subjects: 57
Study 19561484 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein's operation
Number of subjects: 2708
Study 19561484 — intervention group
Group type: COMPARATOR
Intervention: mesh plug repair
Number of subjects: 2708
Study 19561484 — intervention group
Group type: COMPARATOR
Intervention: PHS repair
Number of subjects: 2708
Study 16688654 — intervention group
Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg
Number of subjects: 915
Study 16688654 — intervention group
Group type: COMPARATOR
Intervention: omeprazole 20 mg
Number of subjects: 915
Study 14565994 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training combined with GH administration
Number of subjects: 0
Study 14565994 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 0
Study 14565994 — intervention group
Group type: COMPARATOR
Intervention: GH administration alone
Number of subjects: 0
Study 14565994 — intervention group
Group type: COMPARATOR
Intervention: Resistance training with placebo
Number of subjects: 0
Study 11370690 — intervention group
Group type: EXPERIMENTAL
Intervention: Raspberry leaf tablets (2 x 1.2 g per day)
Number of subjects: 192
Study 11370690 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 9234828 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg + Lisinopril 10 mg
Number of subjects: 156
Study 9234828 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg + Lisinopril 10 mg
Number of subjects: 156
Study 9234828 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg
Number of subjects: 156
Study 9234828 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg
Number of subjects: 156
Study 9234828 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg
Number of subjects: 156
Study 9234828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 29669529 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients Concerns Inventory (PCI) package
Number of subjects: 416
Study 27113362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored patient education intervention (nurse-conducted medication counselling, information booklet, video, website, text message reminders)
Number of subjects: 86
Study 27113362 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored patient education intervention
Number of subjects: 86
Study 27113362 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tailored patient education)
Number of subjects: 86
Study 24408401 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon stimulation test (GST)
Number of subjects: 343
Study 24408401 — intervention group
Group type: COMPARATOR
Intervention: Mixed-meal tolerance test (MMTT)
Number of subjects: 343
Study 22492424 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) 75 U/1.5 mL
Number of subjects: 42
Study 22492424 — intervention group
Group type: COMPARATOR
Intervention: Saline (1.5 mL)
Number of subjects: 42
Study 19664210 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected pregnant women
Number of subjects: 2659
Study 19664210 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected infants
Number of subjects: 2659
Study 16764647 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg twice daily for 14 days
Number of subjects: 69
Study 16764647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 15377480 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) administration after transplantation
Number of subjects: 0
Study 15377480 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11486241 — intervention group
Group type: EXPERIMENTAL
Intervention: Uric acid, 1,000 mg
Number of subjects: 0
Study 11486241 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C, 1,000 mg
Number of subjects: 0
Study 9658668 — intervention group
Group type: EXPERIMENTAL
Intervention: dotarizine (50 mg b.i.d.)
Number of subjects: 110
Study 9658668 — intervention group
Group type: COMPARATOR
Intervention: cinnarizine (75 mg b.i.d.)
Number of subjects: 110
Study 7848586 — intervention group
Group type: COMPARATOR
Intervention: Air exposure
Number of subjects: 28
Study 7848586 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidants (0.12 ppm ozone plus 0.30 ppm nitrogen dioxide)
Number of subjects: 28
Study 7848586 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidants plus sulfuric acid at 70 micrograms/m3 of air
Number of subjects: 28
Study 7848586 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidants plus 0.05 ppm nitric acid
Number of subjects: 28
Study 3394909 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of fentanyl
Number of subjects: 60
Study 3394909 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms of fentanyl
Number of subjects: 60
Study 3394909 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 micrograms of fentanyl
Number of subjects: 60
Study 3394909 — intervention group
Group type: COMPARATOR
Intervention: 2 ml normal saline
Number of subjects: 60
Study 31613050 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin 2.5% with tea tree oil gel
Number of subjects: 47
Study 31613050 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 47
Study 31038461 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based self-management enhancing program (12 months access)
Number of subjects: 157
Study 31038461 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 157
Study 28797867 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression group (CG) with circular-knit sleeves in compression class I (15-21 mm Hg) for daily wearing (n=23)
Number of subjects: 45
Study 28797867 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CG) without compression (n=22)
Number of subjects: 45
Study 28797867 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups underwent a standardized physical exercise program
Number of subjects: 45
Study 25697492 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS reminder for breast self-examination (BSE) - one text message on the first day and another on the fifteenth day of every month for 6 months.
Number of subjects: 202
Study 25697492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS reminders).
Number of subjects: 202
Study 23301947 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression symptoms
Number of subjects: 253
Study 23301947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mania-type symptoms
Number of subjects: 253
Study 20331562 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacetylmorphine (DAM)
Number of subjects: 57
Study 20331562 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 57
Study 20331562 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 57
Study 18645097 — intervention group
Group type: COMPARATOR
Intervention: Freshly reconstituted Botox (control)
Number of subjects: 40
Study 18645097 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week-old reconstituted Botox (experimental) stored at 4 degrees C (refrigerated)
Number of subjects: 40
Study 18645097 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week-old reconstituted Botox (experimental) stored at -20 degrees C (frozen)
Number of subjects: 40
Study 17365349 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based intervention
Number of subjects: 326
Study 17365349 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 326
Study 14764015 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and care interventions
Number of subjects: 88
Study 14764015 — intervention group
Group type: COMPARATOR
Intervention: Care interventions
Number of subjects: 88
Study 14764015 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy
Number of subjects: 88
Study 11386263 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 2289
Study 11386263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2289
Study 9207701 — intervention group
Group type: COMPARATOR
Intervention: Neck resting at neutral position (control)
Number of subjects: 10
Study 9207701 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive hyperflexion of the neck
Number of subjects: 10
Study 9207701 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperextension of the neck with simultaneous abdominal contraction
Number of subjects: 10
Study 9207701 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained active neck hyperflexion
Number of subjects: 10
Study 9207701 — intervention group
Group type: EXPERIMENTAL
Intervention: Active neck flexion (one-minute period) followed by repeated H reflex evocation at two-minute intervals
Number of subjects: 10
Study 8256468 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy (600 mg of D‐alpha tocopherol per day, 200 micrograms of selenium, and 12 mg of zinc)
Number of subjects: 56
Study 8256468 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antioxidant therapy)
Number of subjects: 56
Study 8256468 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy
Number of subjects: 56
Study 3312029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 45
Study 3312029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus flucloxacillin
Number of subjects: 45
Study 3312029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime plus cephalothin
Number of subjects: 45
Study 31971449 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplicates of unselected patient samples
Number of subjects: 65000
Study 31132331 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP tool for identification of ILNs
Number of subjects: 950
Study 31132331 — intervention group
Group type: COMPARATOR
Intervention: Fleischner reporting macro implementation (2017)
Number of subjects: 950
Study 28577588 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized positive feedback
Number of subjects: 138
Study 28577588 — intervention group
Group type: COMPARATOR
Intervention: Neutral feedback
Number of subjects: 138
Study 25382414 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral parent training
Number of subjects: 0
Study 25382414 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary segmentation procedure (SEARCH)
Number of subjects: 0
Study 23514246 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary radiotherapy (RT) ± chemotherapy
Number of subjects: 68
Study 23514246 — intervention group
Group type: COMPARATOR
Intervention: Transoral robotic surgery (TORS) ± adjuvant [chemo] RT
Number of subjects: 68
Study 21685642 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio and video narrative on mobile phone (UMTS)
Number of subjects: 75
Study 21685642 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio and video narrative on DVD (DVD)
Number of subjects: 75
Study 21685642 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio narrative on MP3 player (M3)
Number of subjects: 75
Study 21685642 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio narrative on CD (CD)
Number of subjects: 75
Study 21685642 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 75
Study 19909492 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial electrical muscle stimulation
Number of subjects: 0
Study 19909492 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16963850 — intervention group
Group type: EXPERIMENTAL
Intervention: Anecortave acetate 30 mg
Number of subjects: 34
Study 16963850 — intervention group
Group type: EXPERIMENTAL
Intervention: Anecortave acetate 15 mg
Number of subjects: 34
Study 16963850 — intervention group
Group type: EXPERIMENTAL
Intervention: Anecortave acetate 3 mg
Number of subjects: 34
Study 16963850 — intervention group
Group type: EXPERIMENTAL
Intervention: Anecortave acetate (all concentrations)
Number of subjects: 34
Study 15072030 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 300 mg orally once daily (LEV group)
Number of subjects: 60
Study 15072030 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid 625 mg three times a day (COA group)
Number of subjects: 60
Study 11458304 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (intervention group)
Number of subjects: 239
Study 11458304 — intervention group
Group type: COMPARATOR
Intervention: Men (control group)
Number of subjects: 239